Skip to content
value.today

Manifold Biotechnologies, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2019
Total raised
$78 M
3 rounds on record
Latest round
$33 M
Nov 2024
First round on record
Jul 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Manifold Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2024$33 MNo. 3$10 to $50 million

Manifold Biotechnologies, Inc.: Raise no. 3, Nov 2024

Investors in this round

10 investors had bought by the notice of Dec 3, 2024: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $33 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gleb Kuznetsov · Executive Officer, Director
  • Pierce Ogden · Executive Officer, Director
  • Jeff Huber · Director
  • Jory Bell · Director
  • Steven Holtzman · Director
  • Steven J. Kafka · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold include the aggregate exercise price of certain warrants to purchase shares of capital stock of the Issuer.”

Signed by Gleb Kuznetsov, Chief Executive Officer. Newest notice filed Dec 3, 2024. Read the notice at the SEC.

equity, optionsSEC
May 2022$40 MNo. 2$10 to $50 million

Manifold Biotechnologies, Inc.: Raise no. 2, May 2022

Investors in this round

13 investors had bought by the notice of Jun 13, 2022: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gleb Kuznetsov · Executive Officer, Director, Promoter
  • Pierce Ogden · Executive Officer, Director, Promoter
  • Jeff Huber · Director
  • Jory Bell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gleb Kuznetsov, Chief Executive Officer. Newest notice filed Jun 13, 2022. Read the notice at the SEC.

equitySEC
Jul 2020$5 MNo. 1$2 to $10 million

Manifold Biotechnologies, Inc.: Raise no. 1, Jul 2020

Investors in this round

6 investors had bought by the notice of Aug 13, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gleb Kuznetsov · Executive Officer, Director, Promoter
  • Pierce Ogden · Executive Officer, Director, Promoter
  • Jory Bell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gleb Kuznetsov, Chief Executive Officer. Newest notice filed Aug 13, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Manifold Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2024).

    SEC Form D · Dec 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Manifold Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Manifold Biotechnologies, Inc.
NameRoleNamed in
Gleb KuznetsovExecutive officerDec 2024
Pierce OgdenExecutive officerDec 2024
Gleb KuznetsovDirectorDec 2024
Jeff HuberDirectorDec 2024
Jory BellDirectorDec 2024
Pierce OgdenDirectorDec 2024
Steven HoltzmanDirectorDec 2024
Steven J. KafkaDirectorDec 2024
Gleb KuznetsovPromoterJun 2022
Pierce OgdenPromoterJun 2022